×
QQQ   286.19 (-2.14%)
AAPL   139.04 (-1.85%)
MSFT   259.13 (-2.17%)
META   164.36 (-3.03%)
GOOGL   2,253.46 (-2.73%)
AMZN   108.22 (-4.42%)
TSLA   708.93 (-3.52%)
NVDA   160.89 (-4.62%)
NIO   22.34 (-2.66%)
BABA   116.99 (-1.47%)
AMD   81.02 (-5.97%)
MU   58.44 (-0.58%)
CGC   3.63 (-4.22%)
T   20.72 (-0.29%)
GE   65.91 (-1.20%)
F   11.96 (-0.66%)
DIS   97.55 (+0.97%)
AMC   13.35 (-5.52%)
PFE   50.71 (-2.26%)
PYPL   73.53 (-3.17%)
NFLX   181.91 (-3.82%)
QQQ   286.19 (-2.14%)
AAPL   139.04 (-1.85%)
MSFT   259.13 (-2.17%)
META   164.36 (-3.03%)
GOOGL   2,253.46 (-2.73%)
AMZN   108.22 (-4.42%)
TSLA   708.93 (-3.52%)
NVDA   160.89 (-4.62%)
NIO   22.34 (-2.66%)
BABA   116.99 (-1.47%)
AMD   81.02 (-5.97%)
MU   58.44 (-0.58%)
CGC   3.63 (-4.22%)
T   20.72 (-0.29%)
GE   65.91 (-1.20%)
F   11.96 (-0.66%)
DIS   97.55 (+0.97%)
AMC   13.35 (-5.52%)
PFE   50.71 (-2.26%)
PYPL   73.53 (-3.17%)
NFLX   181.91 (-3.82%)
QQQ   286.19 (-2.14%)
AAPL   139.04 (-1.85%)
MSFT   259.13 (-2.17%)
META   164.36 (-3.03%)
GOOGL   2,253.46 (-2.73%)
AMZN   108.22 (-4.42%)
TSLA   708.93 (-3.52%)
NVDA   160.89 (-4.62%)
NIO   22.34 (-2.66%)
BABA   116.99 (-1.47%)
AMD   81.02 (-5.97%)
MU   58.44 (-0.58%)
CGC   3.63 (-4.22%)
T   20.72 (-0.29%)
GE   65.91 (-1.20%)
F   11.96 (-0.66%)
DIS   97.55 (+0.97%)
AMC   13.35 (-5.52%)
PFE   50.71 (-2.26%)
PYPL   73.53 (-3.17%)
NFLX   181.91 (-3.82%)
QQQ   286.19 (-2.14%)
AAPL   139.04 (-1.85%)
MSFT   259.13 (-2.17%)
META   164.36 (-3.03%)
GOOGL   2,253.46 (-2.73%)
AMZN   108.22 (-4.42%)
TSLA   708.93 (-3.52%)
NVDA   160.89 (-4.62%)
NIO   22.34 (-2.66%)
BABA   116.99 (-1.47%)
AMD   81.02 (-5.97%)
MU   58.44 (-0.58%)
CGC   3.63 (-4.22%)
T   20.72 (-0.29%)
GE   65.91 (-1.20%)
F   11.96 (-0.66%)
DIS   97.55 (+0.97%)
AMC   13.35 (-5.52%)
PFE   50.71 (-2.26%)
PYPL   73.53 (-3.17%)
NFLX   181.91 (-3.82%)
NASDAQ:MGTA

Magenta Therapeutics Stock Forecast, Price & News

$1.25
+0.02 (+1.63%)
(As of 06/28/2022 11:46 AM ET)
Add
Compare
Today's Range
$1.25
$1.27
50-Day Range
$0.97
$1.89
52-Week Range
$0.92
$10.84
Volume
130 shs
Average Volume
352,114 shs
Market Capitalization
$73.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.17
30 days | 90 days | 365 days | Advanced Chart

Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Stock Forecast (MarketRank)

Overall MarketRank

2.21 out of 5 stars

Medical Sector

363rd out of 1,436 stocks

Pharmaceutical Preparations Industry

157th out of 687 stocks

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Magenta Therapeutics logo

About Magenta Therapeutics (NASDAQ:MGTA)

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MGTA Stock News Headlines

Magenta Therapeutics GAAP EPS of -$0.39
Magenta Therapeutics Trims R&D, Cuts Workforce
Stem cell startup cuts staff by 14%
Recap: Magenta Therapeutics Q4 Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTA
Fax
N/A
Employees
75
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$8.17
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+553.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-71.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.94 per share

Miscellaneous

Free Float
49,873,000
Market Cap
$73.50 million
Optionable
Not Optionable
Beta
2.25














Magenta Therapeutics Frequently Asked Questions

Should I buy or sell Magenta Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Magenta Therapeutics stock.
View analyst ratings for Magenta Therapeutics
or view top-rated stocks.

What is Magenta Therapeutics' stock price forecast for 2022?

6 Wall Street analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their MGTA stock forecasts range from $2.00 to $20.00. On average, they expect Magenta Therapeutics' stock price to reach $8.17 in the next twelve months. This suggests a possible upside of 553.3% from the stock's current price.
View analysts' price targets for Magenta Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Magenta Therapeutics' stock performed in 2022?

Magenta Therapeutics' stock was trading at $4.43 at the beginning of 2022. Since then, MGTA shares have decreased by 71.8% and is now trading at $1.25.
View the best growth stocks for 2022 here
.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Magenta Therapeutics
.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.05.
View Magenta Therapeutics' earnings history
.

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Dr. Jason Gardner DPHIL, Ph.D., Co-Founder, CEO, Pres & Director (Age 50, Pay $850.45k)
  • Mr. David Wayne Nichols, Chief Technical Officer (Age 58, Pay $388.92k)
  • Mr. Thomas W. Beetham J.D., MBA, Chief Legal Officer & Sec. (Age 52, Pay $517.61k)
  • Mr. Stephen F. Mahoney J.D., MBA, Chief Financial & Operating Officer and Treasurer (Age 51)
  • Dr. Lisa M. Olson Ph.D., Head of Research & Chief Scientific Officer (Age 62)
  • Mr. Jim Haney, Sr. Director of Investor Relations
  • Lyndsey Scull, Director of Corp. Communications
  • Ms. Kristen Stants, Chief People Officer (Age 49) (LinkedIn Profile)
  • Ms. Catherine Monaghan, Head of Clinical Devel. Operations
  • Ms. Caren Deardorf, Chief Commercial Officer (Age 57)

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics CEO Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among Magenta Therapeutics' employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deep Track Capital LP (9.11%), Gilder Gagnon Howe & Co. LLC (5.75%), BlackRock Inc. (3.63%), Vanguard Group Inc. (3.16%), Wellington Management Group LLP (2.22%) and Woodline Partners LP (1.35%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr, Kristen Stants and Michael P Cooke.
View institutional ownership trends for Magenta Therapeutics
.

Which major investors are selling Magenta Therapeutics stock?

MGTA stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Vanguard Group Inc., BlackRock Inc., Harbor Capital Advisors Inc., State Street Corp, Goldman Sachs Group Inc., and Northern Trust Corp.
View insider buying and selling activity for Magenta Therapeutics
or view top insider-selling stocks.

Which major investors are buying Magenta Therapeutics stock?

MGTA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Woodline Partners LP, Deep Track Capital LP, Renaissance Technologies LLC, Federated Hermes Inc., Integral Health Asset Management LLC, JPMorgan Chase & Co., and Cheyne Capital Management UK LLP.
View insider buying and selling activity for Magenta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $1.25.

How much money does Magenta Therapeutics make?

Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $73.50 million. The company earns $-71.14 million in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Magenta Therapeutics have?

Magenta Therapeutics employs 75 workers across the globe.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Magenta Therapeutics is www.magentatx.com. The company can be reached via phone at (857) 242-0170 or via email at [email protected].

This page (NASDAQ:MGTA) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.